Varlilumab: A Deep Dive into CDX-1127 and its Mechanism The antibody (formerly known as PRT-052) represents a novel immunotherapeutic agent targeting CD27. The drug's mechanism depends on binding to CD27, a cell https://www.targetmol.com/compound/varlilumab